Summary: | Genetically-engineered mouse models (GEMMs) lacking diseased-associated gene(s) globally or in a tissue-specific manner represent an attractive tool with which to assess the efficacy and toxicity of targeted pharmacological inhibitors. <i>Stat3</i> and <i>Stat5a/b</i> transcription factors have been implicated in several pathophysiological conditions, and pharmacological inhibition of both transcription factors has been proposed to treat certain diseases, such as malignancies. To model combined inhibition of <i>Stat3</i> and <i>Stat5a/b</i> we have developed a GEMM harboring a flox <i>Stat3</i>-<i>Stat5a/b</i> allele (<i>Stat5/3<sup>loxP/loxP</sup></i> mice) and generated mice lacking <i>Stat3</i> and <i>Stat5a/b</i> in hepatocytes (<i>Stat5/3<sup>Δhep</sup></i><sup>/<i>Δhep</i></sup>). <i>Stat5/3<sup>Δhep/Δhep</sup></i> mice exhibited a marked reduction of STAT3, STAT5A and STAT5B proteins in the liver and developed steatosis, a phenotype that resembles mice lacking <i>Stat5a/b</i> in hepatocytes. In addition, embryonic deletion of <i>Stat3</i> and <i>Stat5a/b</i> (<i>Stat5/3<sup>Δ</sup></i><sup>/<i>Δ</i></sup> mice) resulted in lethality, similar to <i>Stat3<sup>Δ</sup></i><sup>/<i>Δ</i></sup> mice. This data illustrates that <i>Stat5/3<sup>loxP/loxP</sup></i> mice are functional and can be used as a valuable tool to model the combined inhibition of <i>Stat3</i> and <i>Stat5a/b</i> in tumorigenesis and other diseases.
|